Technology Offer




Radiopharmaceutical for low-cost, high-sensitivity diagnosis of early-stage dementia and tissue viability in acute stroke

Reference Number: TO 21-00011

A Company of the Life-Science Foundation for the Promotion of Science and Research

Challenge

Neuronal activity critically depends on transmembrane potassium (K^+) fluxes and on the maintenance of intra- to extracelluar K^+ -gradients. K^+ -fluxes increase with increasing activity. K^+ -equilibrium potentials – and intracellular K^+ -contents - change with changes in membrane potential that can occur upon long-term up- or down-regulations of electrical



Distribution of Thallium after injection in rat brain at 15 min (A,B) and 7 days (C,D) after introduction in cerebral ischemia. The asterisk in B indicates the center of the ischemia.

activity. Breakdown of K^+ -gradients indicates failure of energy supply. Conversely, maintenance of K^+ -gradients is a viability marker. In addition, clearance of K^+ out of the brain is related to the integrity of the blood-brain barrier (BBB).

Brain K⁺-metabolism thus is of fundamental clinical relevance. In particular, imaging the spatial patterns of chronically up- or down-regulated neuronal activity and of transport rates across the BBB in early stages of dementia as well as tissue viability in acute stroke are of substantial interest in neurology. Attempts have been made to image cerebral K⁺-content using magnetic resonance imaging of 42K, but the technique is insensitive and not able to image the dynamics of K⁺-uptake and -excretion. In principle, K⁺-turnover can be imaged using the well-

established K⁺-probe ²⁰¹Thallium (²⁰¹Tl⁺, or simply ²⁰¹Tl), a radionuclide suitable for detection with single-photon emission computed tomography (SPECT). SPECT is a relatively inexpensive widely available clinical imaging modality that, with newest generation scanners, can provide the same spatial resolution as positron emission tomography (PET). ²⁰¹Tl-SPECT is in use since many decades for imaging myocardial ischemia and infarction. The transport of ²⁰¹Tl through the BBB, however, is slow and only minute amounts of ²⁰¹Tl can be found in the brain in the first hours after intravenous injection of ²⁰¹Tl chloride. Without catalyzing the transport of ²⁰¹Tl through the BBB, the radionuclide cannot be used for imaging brain K⁺-metabolism.

Technology

The lipophilic diethyldithiocarbamate anion (termed DDC⁻ or DEDTC⁻) catalyzes the transport of ²⁰¹Tl⁺ through the BBB. ²⁰¹Tl⁺ and DDC⁻ reversibly form the electroneutral lipophilic chelate complex ²⁰¹TlDDC that passes the BBB. ²⁰¹Tl-content in the brain shortly after intravenous ²⁰¹TlDDC injection is about 100 times higher than after ²⁰¹Tl chloride injection.

After passage through the BBB, 201 Tl is released from the compound. Neurons and astrocytes take up the Tl⁺-ion and the kinetics of Tl⁺-efflux from the brain mimic the kinetics of the slow K⁺-efflux. The relatively long half-life of 201 Tl of 72 hours makes it possible to monitor uptake, redistribution and clearance from the brain over at least 24h.

We have shown, in mouse models of dementia, that after intravenous 201 TIDDC injection both initial brain uptake patterns of 201 TI and the kinetics of 201 TI-loss differ from those in wild-type mice, and that monitoring the 201 TI-loss kinetics provides additional information not contained in the early images. Both, 201 TI-uptake and -loss, were also severely altered in rodent stroke models, and our data show that 201 TI-retention after 201 TIDDC injection can serve as a viability-marker.

Berlin Braunschweig Hamburg Hanover Munich Neuherberg

Ascenion GmbH Herzogstraße 64 D-80803 Munich T +49 (0) 89 31 88 14 - 0 F +49 (0) 89 31 88 14 - 20 info@ascenion.de www.ascenion.de Synthesis of ²⁰¹TIDDC is a quick one-step procedure that works by just mixing ²⁰¹TI+ with sodium diethyldithiocarbamate (NaDDC). DDC⁻ is an inexpensive compound. It is well-known in medicine as it is generated in vivo from Disulfiram (Antabus[©]), which is prescribed in doses far exceeding those needed for SPECT-imaging.

²⁰¹TIDDC is a radiopharmaceutical for SPECT-imaging of brain K⁺-metabolism easily synthesized from two well-characterized components. Compared to SPECT-imaging of cerebral blood flow and PET-imaging of glucose metabolism it offers an additional dimension by imaging not only the uptake but also the kinetics of redistribution and clearance from the brain.

Commercial Opportunity

In-licensing (exclusive or non-exclusive) is possible.

Developmental Status

Pre-clinical studies completed (see Reference Literature), ready to submit for clinical trial.

Patent situation

Patents have been granted in Europe, US and Korea with priority of 2005.

Reference Literature

Goldschmidt J et al. (2010) High-resolution mapping of neuronal activity using the lipophilic thallium chelate complex TIDDC: protocol and validation of the method. NeuroImage 49:303-15.

Wanger T et al. (2012) The use of thallium diethyldithiocarbamate for mapping CNS potassium metabolism and neuronal activity: Tl+ -redistribution, Tl+ -kinetics and Tl+ -equilibrium distribution. J Neurochem 122:106-14.

Lison H et al- (2014) Disrupted cross-laminar cortical processing in β amyloid pathology precedes cell death. Neurobiol Dis 63:62-73.

Stöber F et al. (2014) Single-cell resolution mapping of neuronal damage in acute focal cerebral ischemia using thallium autometallography. J Cereb Blood Flow Metab 34:144-152.

Goldschmidt J et al. (2017) BMBF-Vorhaben "Validierung des Innovationspotenzials wissenschaftlicher Forschung – VIP" – ²⁰¹TIDDC-SPECT zur Frühdiagnostik dementieller Erkrankungen, Abschlussbericht. Technische Informationsbibliothek 2017 (BMBF funded project, validation of the innovative potential of scientific research – ²⁰¹TIDDC-SPECT for early diagnosis of dementias, final report).

Stöber et al. in preparation: SPECT-imaging of K⁺-metabolism in acute cerebral ischemia using ²⁰¹TIDDC, a lipophilic chelate complex of the K⁺-probe ²⁰¹Tl⁺.

Contact: Dr. Torben Söker Email: soeker@ascenion.de T: +49 511 532-8918 F: +49 511 532-8929